- Retrophin (RTRX +0.1%) expects net product sales for the Q4 2018 to be ~$44M. For FY 2018, the Company expects total net product sales of ~$164M. The Company also provided anticipated milestones for 2019.
- Program Updates and Anticipated 2019 Milestones
- Phase 3 FORT Study: Top-line data expected in Q3 2019.
- Top-line data for Phase 2 proof-of-concept study evaluating CNSA-001 in patients with phenylketonuria expected in H1 2019.
- The NDA for a new, more patient-friendly formulation of Thiola is currently under review by the FDA with an assigned PDUFA target action date of June 30, 2019. Pending approval, the Company expects to begin marketing the new formulation in the second half of 2019.
- The Company expects that the PROTECT study will complete enrollment of ~280 patients with IgAN in H1 2021. Top-line data from the 36-week primary endpoint efficacy analysis of proteinuria is expected in H1 2022.
- In late February, the Company expects to announce final financial results from Q4 and FY 2018, as well as provide a corporate update.
- #JPM19
- Now read: Aurinia Pharmaceuticals: Update To Thesis And 2019 Outlook
Original article